SG10201901167SA - Methods and compositions for treatment of attention deficit disorder - Google Patents
Methods and compositions for treatment of attention deficit disorderInfo
- Publication number
- SG10201901167SA SG10201901167SA SG10201901167SA SG10201901167SA SG10201901167SA SG 10201901167S A SG10201901167S A SG 10201901167SA SG 10201901167S A SG10201901167S A SG 10201901167SA SG 10201901167S A SG10201901167S A SG 10201901167SA SG 10201901167S A SG10201901167S A SG 10201901167SA
- Authority
- SG
- Singapore
- Prior art keywords
- attention deficit
- treatment
- methods
- compositions
- deficit disorder
- Prior art date
Links
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title abstract 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title abstract 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 title abstract 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000003111 delayed effect Effects 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 230000001174 ascending effect Effects 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466684P | 2011-03-23 | 2011-03-23 | |
| US201161561763P | 2011-11-18 | 2011-11-18 | |
| US201261591129P | 2012-01-26 | 2012-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201901167SA true SG10201901167SA (en) | 2019-03-28 |
Family
ID=46879766
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201901167SA SG10201901167SA (en) | 2011-03-23 | 2012-03-23 | Methods and compositions for treatment of attention deficit disorder |
| SG2013071279A SG193587A1 (en) | 2011-03-23 | 2012-03-23 | Methods and compositions for treatment of attention deficit disorder |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013071279A SG193587A1 (en) | 2011-03-23 | 2012-03-23 | Methods and compositions for treatment of attention deficit disorder |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9028868B2 (OSRAM) |
| EP (4) | EP4316488A3 (OSRAM) |
| JP (7) | JP6043785B2 (OSRAM) |
| KR (2) | KR20160135373A (OSRAM) |
| CN (2) | CN110151731A (OSRAM) |
| AU (3) | AU2012230733B2 (OSRAM) |
| BR (1) | BR112013024401B1 (OSRAM) |
| CA (1) | CA2830788C (OSRAM) |
| DK (3) | DK2688557T3 (OSRAM) |
| ES (3) | ES2644942T3 (OSRAM) |
| MX (4) | MX2021000431A (OSRAM) |
| PT (3) | PT4011364T (OSRAM) |
| SG (2) | SG10201901167SA (OSRAM) |
| WO (1) | WO2012129551A1 (OSRAM) |
| ZA (1) | ZA201307649B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9498447B2 (en) * | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9119809B2 (en) * | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US10905652B2 (en) * | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US10292937B2 (en) * | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| GB201319791D0 (en) * | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| CA2902911C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| KR102790656B1 (ko) * | 2015-05-04 | 2025-04-02 | 컨플루언스 파마슈티컬스, 엘엘씨 | 아캄프로세이트의 스프링클 제형 |
| US12472149B2 (en) | 2015-07-17 | 2025-11-18 | BE Pharbel Manufacturing | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form |
| ES2944568T3 (es) * | 2015-07-17 | 2023-06-22 | Be Pharbel Mfg | Micropartículas multicapa de liberación de compuestos farmacéuticamente activos en forma de dosificación líquida |
| WO2017027778A1 (en) | 2015-08-13 | 2017-02-16 | Temple University-Of The Commonwealth System Of Higher Education | Calcium alginate dosage formulations, and methods of making and using thereof |
| US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
| WO2017173068A1 (en) * | 2016-03-30 | 2017-10-05 | University Of Maryland, Baltimore | Microparticulate system for colonic drug delivery |
| US9827233B1 (en) * | 2016-05-26 | 2017-11-28 | Ovid Therapeutics Inc | Methods of treating behavioral syndromes using pipradrol |
| US12274794B2 (en) * | 2016-07-06 | 2025-04-15 | Orient Pharma Co., Ltd. | Oral dosage form with drug composition, barrier layer and drug layer |
| US9931303B1 (en) * | 2017-02-06 | 2018-04-03 | Alcobra Ltd. | Abuse deterrent formulations of amphetamine |
| US20180256515A1 (en) * | 2017-03-10 | 2018-09-13 | Adare Pharmaceuticals, Inc. | Oral amphetamine composition |
| US12036315B2 (en) | 2017-04-28 | 2024-07-16 | Astellas Pharma Inc. | Pharmaceutical composition for oral administration comprising enzalutamide |
| AU2018269557B2 (en) * | 2017-05-17 | 2021-06-03 | Confluence Pharmaceuticals, Llc | Formulations of homotaurines and salts thereof |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| EP3459528B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Preparation of solid dosage forms comprising antibodies by solution/suspension layering |
| CN108653243B (zh) * | 2018-03-30 | 2019-03-22 | 江苏南农高科动物药业有限公司 | 一种缓释替米考星微囊粉的制备方法 |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| EP3662901B1 (en) | 2018-12-07 | 2025-01-01 | Tillotts Pharma AG | Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing |
| EP3662900A1 (en) * | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Colonic drug delivery formulation |
| CN113891713A (zh) * | 2019-01-25 | 2022-01-04 | 艾伦索尔医药发展股份有限公司 | 用于治疗注意力缺陷多动障碍的哌甲酯组合物 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8322007D0 (en) | 1983-08-16 | 1983-09-21 | Wellcome Found | Pharmaceutical delivery system |
| US4904476A (en) | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5474783A (en) | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| GB2230442B (en) | 1989-02-16 | 1992-11-25 | Nat Res Dev | Controlled release device |
| JP2558396B2 (ja) | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
| US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
| NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| JP2916978B2 (ja) | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
| US5658590A (en) | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| IT1276689B1 (it) | 1995-06-09 | 1997-11-03 | Applied Pharma Res | Forma farmaceutica solida ad uso orale |
| GB9514451D0 (en) | 1995-07-14 | 1995-09-13 | Chiroscience Ltd | Sustained-release formulation |
| US6355656B1 (en) | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
| US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
| US5922736A (en) | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| MX9805870A (OSRAM) | 1996-01-22 | 1999-01-31 | ||
| ES2187753T3 (es) | 1996-02-02 | 2003-06-16 | Medeva Europ Ltd | Procedimiento para la preparacion de d-treo-(r;r)-metilfenidato y para el reciclaje de enantiomeros no deseados mediante epimerizacion. |
| JP4138005B2 (ja) | 1996-03-08 | 2008-08-20 | メデバ・ユアラプ・リミテッド | トレオーメチルフェニデートの分割 |
| GB9606417D0 (en) | 1996-03-27 | 1996-06-05 | Chiroscience Ltd | Asymmetric cyclisation |
| DE69735581T2 (de) | 1996-09-30 | 2007-01-25 | Alza Corp., Palo Alto | Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung |
| US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| PT946151E (pt) | 1996-11-25 | 2006-07-31 | Alza Corp | Forma de dosagem de dose crescente |
| EP1782798A3 (en) | 1996-11-25 | 2008-05-21 | Alza Corporation | Ascending-dose dosage form |
| JP2001506621A (ja) | 1996-12-13 | 2001-05-22 | メデバ・ユアラプ・リミテッド | エナンチオマー濃縮されたトレオ−メチルフェニデートの調製法 |
| GB9700912D0 (en) | 1997-01-17 | 1997-03-05 | Chiroscience Ltd | Resolution |
| US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
| JP2002525311A (ja) * | 1998-10-01 | 2002-08-13 | エラン ファーマ インターナショナル，リミティド | 徐放性ナノ粒子組成物 |
| US6322819B1 (en) | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
| KR20070051953A (ko) | 1998-11-02 | 2007-05-18 | 엘란 코포레이션, 피엘씨 | 다입자 변형 방출 조성물 |
| US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| US6733789B1 (en) | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
| US8545880B2 (en) * | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
| US6384020B1 (en) | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
| US6500459B1 (en) | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
| GB9918735D0 (en) * | 1999-08-09 | 1999-10-13 | Straken Limited | Transdermal patches |
| US6898455B2 (en) | 1999-10-29 | 2005-05-24 | The Mclean Hospital Corporation | Method for providing optimal drug dosage |
| US7108866B1 (en) | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
| US6569456B2 (en) | 2000-01-13 | 2003-05-27 | Osmotica Corp. | Osmotic device containing diltiazem and an ACE inhibitor or diuretic |
| US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| US6520921B1 (en) | 2000-06-20 | 2003-02-18 | Eastman Kodak Company | Method for determining attention deficit hyperactivity disorder (ADHD) medication dosage and for monitoring the effects of (ADHD) medication |
| US6344215B1 (en) * | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
| US20030232890A1 (en) | 2000-11-01 | 2003-12-18 | Sention, Inc. | Methods for treating an impairment in memory consolidation |
| US6287599B1 (en) | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| US20040137062A1 (en) | 2001-05-25 | 2004-07-15 | Sham Chopra | Chronotherapy tablet and methods related thereto |
| EA005537B1 (ru) | 2001-07-10 | 2005-04-28 | Тева Фармасьютикал Индастриес Лтд. | Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата |
| US7157103B2 (en) | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
| US6811794B2 (en) | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| US6726624B2 (en) | 2002-03-06 | 2004-04-27 | The Mclean Hospital Corporation | Method and apparatus for determining attention deficit hyperactivity disorder (adhd) medication dosage and for monitoring the effects of adhd medication on people who have adhd using complementary tests |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| CA2496837A1 (en) | 2002-09-09 | 2004-03-18 | Biovail Laboratories Inc. | Chronotherapeutic diltiazem formulations and the administration thereof |
| US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
| US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
| US7910128B2 (en) | 2003-01-03 | 2011-03-22 | Supernus Pharmaceuticals, Inc. | Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics |
| AU2004251647B2 (en) | 2003-05-29 | 2010-01-14 | Takeda Pharmaceutical Company Limited | Abuse resistant amphetamine compounds |
| US20050031688A1 (en) | 2003-08-04 | 2005-02-10 | Ayala William J. | Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration |
| EP1713797B1 (en) | 2004-01-29 | 2008-03-05 | Pfizer, Inc. | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity |
| ES2261006B1 (es) * | 2004-06-10 | 2007-11-01 | Laboratorios Rubio, S.A. | Pellet multicapa de liberacion controlada de metilfenidato. |
| EP1846040A2 (en) | 2005-01-28 | 2007-10-24 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| FR2892937B1 (fr) * | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | Forme pharmaceutique orale microparticulaire anti-mesusage |
| PL2457562T3 (pl) * | 2006-05-09 | 2017-09-29 | Mallinckrodt Llc | Stałe postacie dawkowania leku o zmodyfikowanym uwalnianiu o kinetyce rzędu zerowego |
| US8846100B2 (en) * | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
| MX2008014455A (es) * | 2006-05-12 | 2008-11-27 | Shire Llc | Sistema de suministro de farmaco de dosis controlada. |
| FR2901478B1 (fr) * | 2006-05-24 | 2015-06-05 | Flamel Tech Sa | Forme pharmaceutique orale multimicroparticulaire a liberation prolongee |
| CN1985810A (zh) * | 2006-07-28 | 2007-06-27 | 中国人民解放军第二军医大学 | 盐酸哌甲酯缓控释胶囊及其制备方法 |
| KR100888131B1 (ko) | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
| CA2664893C (en) | 2006-10-30 | 2015-01-27 | Hanall Pharmaceutical Company, Ltd. | Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors |
| WO2008122965A2 (en) | 2007-04-04 | 2008-10-16 | Sigmoid Pharma Limited | Pharmaceutical cyclosporin compositions |
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| JP5774853B2 (ja) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 医薬投薬形 |
| CA2627198A1 (en) | 2008-03-27 | 2009-09-27 | Pharmascience Inc. | Methylphenidate extended release therapeutic drug delivery system |
| WO2011041414A1 (en) | 2009-09-30 | 2011-04-07 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
-
2012
- 2012-03-23 EP EP23215283.5A patent/EP4316488A3/en active Pending
- 2012-03-23 CN CN201910483969.1A patent/CN110151731A/zh active Pending
- 2012-03-23 AU AU2012230733A patent/AU2012230733B2/en active Active
- 2012-03-23 EP EP12760068.2A patent/EP2688557B1/en active Active
- 2012-03-23 PT PT211742192T patent/PT4011364T/pt unknown
- 2012-03-23 CA CA2830788A patent/CA2830788C/en active Active
- 2012-03-23 CN CN201280024451.8A patent/CN103608004A/zh active Pending
- 2012-03-23 WO PCT/US2012/030472 patent/WO2012129551A1/en not_active Ceased
- 2012-03-23 KR KR1020167032196A patent/KR20160135373A/ko not_active Ceased
- 2012-03-23 EP EP17187023.1A patent/EP3272342B1/en active Active
- 2012-03-23 DK DK12760068.2T patent/DK2688557T3/da active
- 2012-03-23 US US13/429,292 patent/US9028868B2/en active Active
- 2012-03-23 MX MX2021000431A patent/MX2021000431A/es unknown
- 2012-03-23 ES ES12760068.2T patent/ES2644942T3/es active Active
- 2012-03-23 SG SG10201901167SA patent/SG10201901167SA/en unknown
- 2012-03-23 DK DK21174219.2T patent/DK4011364T3/da active
- 2012-03-23 DK DK17187023.1T patent/DK3272342T3/da active
- 2012-03-23 MX MX2013010920A patent/MX357551B/es active IP Right Grant
- 2012-03-23 PT PT127600682T patent/PT2688557T/pt unknown
- 2012-03-23 ES ES21174219T patent/ES2973539T3/es active Active
- 2012-03-23 KR KR1020137027522A patent/KR101834033B1/ko active Active
- 2012-03-23 JP JP2014501292A patent/JP6043785B2/ja active Active
- 2012-03-23 BR BR112013024401-1A patent/BR112013024401B1/pt active IP Right Grant
- 2012-03-23 MX MX2018008611A patent/MX383127B/es unknown
- 2012-03-23 EP EP21174219.2A patent/EP4011364B1/en active Active
- 2012-03-23 PT PT171870231T patent/PT3272342T/pt unknown
- 2012-03-23 ES ES17187023T patent/ES2883589T3/es active Active
- 2012-03-23 SG SG2013071279A patent/SG193587A1/en unknown
-
2013
- 2013-09-23 MX MX2022013590A patent/MX2022013590A/es unknown
- 2013-10-15 ZA ZA2013/07649A patent/ZA201307649B/en unknown
-
2016
- 2016-03-23 JP JP2016058474A patent/JP2016117767A/ja not_active Withdrawn
- 2016-09-16 AU AU2016228307A patent/AU2016228307A1/en not_active Abandoned
-
2017
- 2017-05-01 JP JP2017091305A patent/JP6325148B2/ja active Active
-
2018
- 2018-03-21 AU AU2018202002A patent/AU2018202002B2/en active Active
- 2018-09-25 JP JP2018179001A patent/JP2018197276A/ja not_active Withdrawn
-
2020
- 2020-03-02 JP JP2020035076A patent/JP2020079322A/ja not_active Withdrawn
-
2022
- 2022-03-01 JP JP2022030878A patent/JP2022066315A/ja not_active Withdrawn
-
2023
- 2023-12-28 JP JP2023223409A patent/JP2024019726A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201901167SA (en) | Methods and compositions for treatment of attention deficit disorder | |
| SG10201902353UA (en) | Capturing specific nucleic acid materials from individual biological cells in a micro-fluidic device | |
| PH12015501404A1 (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| NZ595046A (en) | Compositions and methods for extended therapy with aminopyridines | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| PH12012502082A1 (en) | Combination of active loaded granules with additional actives | |
| MD20140004A2 (en) | Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| NZ613264A (en) | Use of vitamin k for weight maintenance and weight control | |
| TN2013000503A1 (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| IN2013MU01239A (OSRAM) | ||
| UA66406U (ru) | Способ лечения остеопенического синдрома у беременных с перинатальным инфицированием | |
| IN2013MU01944A (OSRAM) | ||
| IN2013MU01241A (OSRAM) | ||
| IN2013MU01240A (OSRAM) | ||
| IN2013MU01242A (OSRAM) | ||
| UA85403U (ru) | Способ лечения больных депрессивными расстройствами средней степени в климактерическом периоде | |
| MY166773A (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| UA89772U (ru) | Способ лечения кори у детей | |
| TN2011000096A1 (en) | Method for delivering a pharmaceutical composition to patient in need thereof | |
| IN2013MU01251A (OSRAM) |